This past week, BEVIMI was officially announced. This new company aims to bring pharmaceutical-style rigor to the consumer brain-health market. Headquartered in Greenwich, Connecticut and led by co-founders Paul Jacobson (CEO; formerly CEO of Thorne HealthTech) and Joel Dudley, PhD (President; genetics/genomics and biomedical informatics leader with time at Tempus and in academia), BEVIMI is positioning itself at the intersection of nutritional intervention, diagnostics, and AI.

Out of pure interest I researched a bit the Brain Health & Cognitive Wellness space BEVIMI is entering. Here is a summary of my early findings.

What We Know

Mission & Model

BEVIMI, a new company focused on brain health and cognitive wellness. Their mission is to strengthen minds and improve quality of life through preventative health by combining multi-ingredient nutritional formulations with diagnostics, biomarkers, education, and AI-driven insights.

Cognitive health is of particular importance in the later stage of life. Cognitive health is vital to maintain independence, quality of life, and overall well-being. Good cognitive health also reduces the risk of developing severe cognitive issues, such as dementia, and promotes better mental and physical health. Focusing on cognitive health helps people cope with normal age-related changes and supports their ability to continue living fulfilling lives. 

First Product of BEVIMI

Their first product, launching in early 2026, is a 2-ounce nutritional support beverage designed for individuals at high risk of or in the preclinical stages of Alzheimer’s disease. This beverage contains bioactive ingredients, including hydrophobic compounds, with focus on bioavailability, blood-brain barrier (BBB) engagement, and addressing multiple Alzheimer’s disease-relevant pathways. The formulation targets several mechanisms implicated in early cognitive decline, such as neuroinflammation, amyloid-β proteostasis and clearance, BBB integrity, and gut-brain axis metabolites.

BEVIMI’s first product is slated for early 2026.

Evidence Study Plan

BEVIMI plans to study this product in an IRB-approved, randomized, double-blind, placebo-controlled clinical trial. The primary objective is safety and tolerability; secondary and exploratory endpoints including biomarkers relevant to Alzheimer’s pathophysiology. This rigorous approach, if executed as described, would distinguish BEVIMI in consumer category often lacking robust scientific evidence.

Why This Matters

Demand for cognitive wellness and longevity offerings is increasing, particularly among aging populations and individuals with family histories of neurodegenerative disease. However, the current market is crowded with products that often make general claims, rely on small or non-randomized studies, and rarely integrate objective diagnostics to demonstrate efficacy. If BEVIMI truly combines a multi-pathway formulation with biomarker-anchored trials and AI-assisted personalization, it has the potential to redefine standards for brain health. This would move beyond simply “feeling better” to demonstrating measurable changes in accepted markers of disease biology.

The founders’ backgrounds are also noteworthy. Jacobson successfully scaled a leading health-tech supplement company through a public listing, and Dudley has extensive experience in data-driven precision medicine. This blend of translational data sciences and commercial execution established BEVIMI’s “consumer-accessible, clinically serious” approach.

What’s Still Unclear (and Worth Watching)

• Human evidence by pathway: Many compounds show promise in preclinical or mechanistic studies. However, obtaining and measuring human outcomes, especially in preclinical Alzheimer’s Disease, presence a significant challenge.
• Regulatory posture: It will be important to determine whether BEVIMI formulation will be positioned as a dietary supplement, functional beverage, or medical food/Food for Special Purpose (FSMP)? The decision will impact claims, oversight, labeling, and distribution.
• Bioavailability engineering: Delivering hydrophobic active ingredients in effective doses is non-trivial. The company acknowledges this challenge, and the design and supporting data will be matter.
• Formulation transparency: A complete ingredient list or doses are required. While the company has identified target pathways, efficacy and safety will ultimately depend on these specifics.
• Commercial realities: Pricing, accessibility, and the adoption curve for both consumers and clinicians need to be defined. These remain open questions in a highly competitive market.

Where BEVIMI Fits in the Competitive Landscape

BEVIMI aims to occupy the center of the market, which can be envisioned as three overlapping circles: clinically studied nutrition, diagnostics that define risk, and digital tools that monitor change (See Figure 1).

Figure 1: BEVIMI aims to occupy the center of the market.

Closest Comparators (Nutrition with Trials)

• Nestlé Health Science’s BrainXpert: A specialized ketogenic drink being studied in randomized, placebo-controlled trials in Mild Cognitive Impairment (MCI) patients. Nestlé brings scale, R&D muscle, and global distribution, making BrainXpert a direct competitor on format, population, and clinical posture.
  • Earlier studies of Nestlé Health Science’s BrainXpert have been completed (BENEFIC trial, Phase 1) have been completed and their results were published in 2020, showing that the product improved cognitive performance in individuals with mild cognitive impairment (MCI). 
• Nutricia/Danone’s Souvenaid which contains Fortasyn Connect, a blend of omega-3 fatty acids, uridine monophosphate, choline, B vitamins, and other nutrients: This multi-nutrient formulation is designed for prodromal/early AD with multiple randomized controlled trials (RCTs) and meta-analyses showing mixed but meaningful signals over 12–24 months. They have a strong medical-nutrition channels and clinician awareness make this a high bar for newcomers.
  • Note: Danone is the parent company of Nutricia, which operates as a brand specializing in early life and medical nutrition within Danone’s Specialized Nutrition division. Danone acquired the Nutricia brand and it’s products, such as infant formula and therapeutic foods, which are now part of Danone’s health-focused portfolio. 
• Legacy ketogenic “medical food” players like Cerecin with its product Axona: Company shows long-standing interest in metabolism-based support, with the focus on building next-generation ketogenic therapies for neurological and metabolic diseases. Though, the current momentum is more with Nestlé and Danone.
  • Note: Ketogenic medical foods provide specific ratios of fats, proteins, and carbohydrates to induce a state of ketosis, which may benefit cognitive health by providing the brain with an alternative, more efficient fuel source. The primary mechanism by which ketogenic diets affect the brain is via a metabolic shift from using glucose to ketone bodies for fuel which improves brain health through several pathways.

Broader supplement/nootropic brands include companies such as Onnit, HVMN (Ketone-IQ), Natural Factors, Liquid Health, and Quincy Bioscience, all of which command attention as large consumer spend. At the same time, most do not integrate AD diagnostics or run placebo-controlled studies aligned to disease biomarkers. Generally, these consumer-facing products demonstrate light evidence and subjective claims (memory support, mental clarity)  

“BEVIMI’s bet on rigor and measurement is a clear differentiator if it’s followed through.”

Tempus Could Be the Main Enabler for BEVIMI

BEVIMI can, and most certainly will, leverage the Tempus platform with its clinico-genomic data, AI tooling, and provider network to accelerate evidence, personalization, and distribution.

There are several use case scenarios I can think of where this tight relationship could come into play:

• Cohort discovery & market sizing
  • Build an IRB-approved “preclinical/at-risk AD phenotype” from EHR signals (age, family history, MCI codes, cognitive test notes, sleep/metabolic comorbidities, medication patterns) and, where available, blood biomarkers (Aβ42/40, p-tau, NfL, GFAP).
  • Create an output, e.g., heatmap, showing where the right patients are, expected screen-fail rates, and the addressable market by site/region.
• Predictive enrichment & site selection
  • Train models that estimate likelihood of biomarker change and likelihood of adherence given baseline characteristics, e.g., demographics, genetics, clinical test results, and imaging scan
  • Use scores to pick high-yield sites and pre-screen lists → smaller, faster, cheaper RCTs with higher signal-to-noise.
• Recruitment via provider network – actively being used by Tempus
  • Embed trial flags into participating clinics’ workflows (point-of-care prescreen, direct referrals).
  • Pair with a just-in-time site activation pattern, if Tempus supports it, which allows to open sites only where eligible patients surface.
• External comparators / synthetic controls (for supplement-grade evidence, not label claims)
  • Use de-identified RWD to construct matched controls for exploratory analyses, or to refine sample-size/power for future trials.
  • Treat as hypothesis-generating; primary claims still come from the RCT.
• Safety & post-market monitoring
  • Build near–real-time pharmacovigilance-style dashboards: GI events, hepatic/renal labs, allergy codes. All stratified by age, meds, comorbidities.
  • Use this to tighten labeling, contraindications, and clinician guidance.
• Personalization & dosing heuristics
  • With trial and follow-up data, train uplift/causal ML models to suggest which user profiles benefit most and which dose/timing patterns correlate with biomarker shifts.
  • Push simple rules (not black-box claims) into app/CRM system as “best-fit protocols.”
• HEOR for payer & employer pilots
  • Link outcomes to health-care resource use (neuro visits, sleep/mental-health utilization, falls, polypharmacy proxies) to build a cost-offset narrative for self-insured employers or MA plans.
• KOL dashboards & publication engine
  • Site-level dashboards which support screen, enroll, and on-treatment biomarker change and digital cognition trends.
  • Pre-agree on analyses suitable for congress posters/manuscripts to establish scientific credibility.

Additional Enablers and Gatekeepers (Diagnostics & Digital)

Enablers are companies that don’t sell a competing intervention (e.g., a brain-health drink) but allow BEVIMI to possibly reach a larger audience and scale. They supply the tests, measurements, or platforms that BEVIMI would plug into.

• Blood biomarker testing labs (e.g., C2N Diagnostics, Roche): Test specific markers (e.g., amyloid beta (Aβ42/ Aβ 40) ratios, phosphorylated tau (p-tau217), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL)) to identify who is “at risk”, personalize enrollment, and objectively track response/changes over time.
• Digital biomarker platforms (e.g., Altoida, Linus Health): Offer sensitive, at-home cognitive assessments that could complement blood markers in longitudinal monitoring.
• (Sometimes) distribution/data pipes: Clinics, lab networks, or EHR integrations that help reach patients and surface results.

Enablers matter, because they could help control the funnel by determining who qualifies via screening processes, measuring/monitoring progress, and proving credible the outcome.

Positioning summary. If Nestlé and Danone occupy the “clinically studied nutrition” quadrant and C2N/Roche anchor the “diagnostics” axis, BEVIMI’s target is the upper-right corner: high-rigor evidence tightly integrated with diagnostics, and ideally paired with digital assessments, to deliver a measurable prevention-oriented experience (see Figure 2).

Figure 2: BEVIMI Positioning Map: Rigor x Diagnostics Integration

The Thorne HealthTech and Tempus Background

In this section I’ve outlined the key advantages of having former Thorne HealthTech and Tempus leadership as co-founders for BEVIMI.

Having an ex-Thorne HealthTech CEO as a co-founder is a real asset, bringing immediate benefits in quality and manufacturing (e.g., cGMP discipline, reliable CMO selection, know-how on bioavailability for hydrophobic actives). This also includes valuable experience with claims, evidence, and compliance, established go-to-market playbooks, and knowledge of diagnostics-enabled personalization, similar to Thorne’s at-home lab tests. Additionally, it offers supply chain and cost advantages through relationships with tier-1 ingredient suppliers, enhancing investor and partner credibility, which can streamline due diligence and strategic positioning. Ultimately, this leadership can compress BEVIMI’s timeline to a credible, scalable launch, improve COGS/quality, and ensure claims discipline. Dudley’s data and diagnostics expertise further position the product into the upper-right quadrant combining high rigor with diagnostic integration. The ex-Tempus background contributes clinico-genomic and AI capabilities, enabling the tight integration of validated biomarkers and digital assessments. This ensures BEVIMI can deliver a consumer-ready experience with pharma-style rigor and measurable outcomes.

“Pairing ex-Thorne’s cGMP manufacturing, compliant go-to-market, and supplier leverage with ex-Tempus’s AI-and-biomarker engine knowledge lets BEVIMI launch faster and credibly with diagnostics-integrated personalization and pharma-style, measurable outcomes.”

Execution Priorities That Will Make or Break the Story

1. Trial transparency and design discipline: Pre-register the study, publish a statistical analysis plan, power for biomarker change over a realistic timeframe (often 24–36 weeks), and control for diet and lifestyle confounders. Clear criteria for who qualifies as “at risk” (e.g., amyloid positivity or elevated p-tau) will matter.
2. Diagnostic partnerships: Formal relationships with blood-biomarker providers (for screening and on-treatment monitoring) and digital biomarker apps (for home-based cognition) can create an end-to-end “screen to intervene to monitor” journey.
3. Regulatory clarity and claims discipline: Whether supplement or medical nutrition, align all claims, packaging, and marketing to the chosen path. Physician education should center on measurable, clinically relevant endpoints.
4. Evidence-led go-to-market: Build a KOL flywheel around memory clinics, geriatricians, and prevention-minded primary care, while targeting DTC segments (risk-aware 50–70-year-olds and caregivers) with plain-English data rather than generic “memory” messaging.

The Bottom Line

While BEVIMI is stepping into a crowded, but still unsatisfied space, they can show off a credible team, strong partnership with enabler Tempus, and a clear thesis to make prevention tangible by pairing multi-pathway nutrition with objective diagnostics and rigorous trials. If the company executes on transparency, partnerships, and measurable outcomes, it can carve out a differentiated position against entrenched medical-nutrition players and an ocean of lightly evidenced nootropics.

We’ll be watching for three near-term signals: (1) clinical-trial registration details (sites, sample size, endpoints), (2) regulatory posture and claim language, and (3) any financing disclosures and strategic partnerships. If those line up with today’s launch narrative, BEVIMIi could become one of the more interesting attempts to bring precision-health thinking to everyday brain care.

---

Discovery how we can help you with your market, product, and competitive landscape research